INS and Alzheimer disease: The rationale for testing GLP-1RAs in Alzheimer’s disease is straightforward: AD brains are characterized by insulin resistance, reduced energy metabolism, inflammation, and a failure to clear toxic proteins, all processes that are favorably modulated by GLP-1RA signaling.